Home/Stocks/Torrent Pharmaceuticals Ltd.
NSE: TORNTPHARM · Pharma & Health

Torrent Pharmaceuticals Ltd.

4,999.00 2.23%
Open
4,885.00
High
4,999.00
Low
4,877.50
Prev close
4,890.00
Volume
3,17,547

Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →

What Torrent Pharmaceuticals does

Ahmedabad-based pharmaceutical company of the Torrent Group focused on branded generics, with leading therapy presence in cardiovascular, CNS, gastro-intestinal and vitamins/minerals/nutrients. Key markets are India (majority of revenue, strengthened by acquisitions such as Elder's India business, Unichem's India business and Curatio), Brazil, Germany and the US. In 2025 it agreed to acquire a controlling stake in JB Chemicals & Pharmaceuticals from KKR. Revenue is driven by chronic-therapy branded prescriptions and field-force productivity.

A top-tier Indian branded-generics player, consistently ranked among the leaders in the domestic chronic segment.

Listing and classification

NSE symbol
TORNTPHARM
ISIN
INE685A01028
Sector
Pharma & Health
Sub-sector
Pharma
Market-cap tier
Large Cap
Market-cap rank
#63

Torrent Pharmaceuticals Ltd. is a constituent of NIFTY 100, NIFTY 200, NIFTY 500, NIFTY HEALTHCARE, NIFTY NEXT 50, NIFTY PHARMA. See where it sits on the market heatmap →

Financial ratios, as filed

Consolidated annual figures taken from Torrent Pharmaceuticals Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).

Torrent Pharmaceuticals Ltd. — key consolidated ratios by financial year
MetricFY26FY25FY24
EPS (basic, ₹)63.9256.4748.94
Book value / share (₹)519.56224.28202.56
Return on equity12.3%25.2%24.1%
Return on capital employed9.6%28.5%26.6%
Operating margin24.6%25.4%23.9%
Net margin15.3%16.6%15.4%
EBITDA₹4,559 Cr₹3,721 Cr₹3,368 Cr
Free cash flow₹2,346 Cr₹1,974 Cr₹2,833 Cr
Total debt₹14,798 Cr₹3,026 Cr₹3,938 Cr
Debt to equity0.840.400.57
Interest coverage8.911.67.2
Current ratio1.131.191.03
Shares outstanding33,84,60,00033,84,60,00033,84,60,000

Open the full income statement, balance sheet and cash flow for TORNTPHARM

Shareholding pattern

As disclosed for the quarter ended 20 Jul 2026.

Promoter & group
60.78%
FII / FPI
17.97%
DII
12.87%
Public
39.22%

Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →

Peers in Pharma

Companies Alphave classifies in the same sub-sector, closest by market capitalisation.

What this page will not tell you

Whether to buy it
Alphave is NISM-certified, not a SEBI-registered research analyst. There is no target price, rating or recommendation anywhere on this page, and there will not be one.
A forecast of next quarter
Every figure above is filed history. Alphave publishes what companies reported, not what they might report.
Intraday precision
The quote on this page is cached and stamped with its as-of time. For live prices that update while you watch, use the chart.